Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Radiopharm Theranostics Limited ( (AU:RAD) ) is now available.
Radiopharm Theranostics Limited has announced that Paul Hopper has ceased to be a substantial holder in the company as of December 9, 2025. This change was due to a dilution from a placement, which affects the voting securities of the company. The announcement may impact the company’s shareholder structure and could influence its market dynamics.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates in the biotechnology industry, focusing on the development and commercialization of radiopharmaceutical products for diagnostic and therapeutic purposes. The company is listed on the Australian Securities Exchange under the ticker RAD.
Average Trading Volume: 6,150,431
Technical Sentiment Signal: Sell
Current Market Cap: A$61.45M
Learn more about RAD stock on TipRanks’ Stock Analysis page.